AR104172A1 - COMBINATION THERAPY WITH FGFR / PD-1 FOR CANCER TREATMENT - Google Patents
COMBINATION THERAPY WITH FGFR / PD-1 FOR CANCER TREATMENTInfo
- Publication number
- AR104172A1 AR104172A1 ARP160100891A ARP160100891A AR104172A1 AR 104172 A1 AR104172 A1 AR 104172A1 AR P160100891 A ARP160100891 A AR P160100891A AR P160100891 A ARP160100891 A AR P160100891A AR 104172 A1 AR104172 A1 AR 104172A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgfr
- combination therapy
- cancer treatment
- patient
- fgfr inhibitor
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un método para tratar el cáncer en un paciente, que comprende: administrar al paciente una cantidad farmacéuticamente eficaz de un anticuerpo que bloquea la interacción entre PD-1 y PD-L1 y una cantidad farmacéuticamente eficaz de un inhibidor de FGFR, en donde se administran el anticuerpo que bloquea la interacción entre PD-1 y PD-L1 y el inhibidor de FGFR si hay una o más variantes de FGFR presentes en una muestra biológica del paciente. Reivindicación 11: El método de cualquiera de las reivindicaciones anteriores, en donde el inhibidor de FGFR es el compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este.Claim 1: A method of treating cancer in a patient, comprising: administering to the patient a pharmaceutically effective amount of an antibody that blocks the interaction between PD-1 and PD-L1 and a pharmaceutically effective amount of an FGFR inhibitor, in where the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor is administered if one or more variants of FGFR are present in a biological sample of the patient. Claim 11: The method of any of the preceding claims, wherein the FGFR inhibitor is the compound of the formula (1) or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142569P | 2015-04-03 | 2015-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104172A1 true AR104172A1 (en) | 2017-07-05 |
Family
ID=57132876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100891A AR104172A1 (en) | 2015-04-03 | 2016-04-01 | COMBINATION THERAPY WITH FGFR / PD-1 FOR CANCER TREATMENT |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR104172A1 (en) |
| TW (1) | TWI703984B (en) |
| UY (1) | UY36600A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730587A (en) * | 2021-09-23 | 2021-12-03 | 澳门大学 | Application of FGFR and related signal pathway inhibitor thereof in preparation of medicament for treating FGFR2 mutant tumors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| JOP20200094A1 (en) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
-
2016
- 2016-03-31 TW TW105110210A patent/TWI703984B/en active
- 2016-04-01 AR ARP160100891A patent/AR104172A1/en unknown
- 2016-04-01 UY UY0001036600A patent/UY36600A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY36600A (en) | 2016-09-30 |
| TWI703984B (en) | 2020-09-11 |
| TW201642903A (en) | 2016-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17072756A (en) | FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) / PROGRAMMED DEATH 1 (PD-1) COMBINATION THERAPY FOR THE TREATMENT OF CANCER. | |
| CO2020006009A2 (en) | Methods of using ehmt2 inhibitors to treat or prevent blood disorders | |
| AR101740A1 (en) | COMBINATION AND COMPOSITION THERAPY | |
| EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
| CL2018000318A1 (en) | Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925) | |
| BR112018073920A2 (en) | pd-1 / pd-l1 inhibitors for cancer treatment ". | |
| UY35313A (en) | ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS | |
| EA201790142A1 (en) | TREATMENT OF LEUKEMIA INHIBITORS HISTONDEACETYLASE | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| BR112015026297A2 (en) | combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment | |
| BR112017007144A2 (en) | valproic acid or a pharmaceutically acceptable salt thereof, compound, pharmaceutical composition, and, compound or composition for use, use, method or composition. | |
| EA201790576A1 (en) | Spirocyclic inhibitors of katepsin C | |
| EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
| AR097619A1 (en) | USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS | |
| CO2019009000A2 (en) | Pharmaceutical combinations to treat cancer | |
| EA201791933A1 (en) | INHIBITION OF OLIG2 ACTIVITY | |
| AR087902A1 (en) | COMPOSITIONS AND METHODS TO TREAT CANCER USING THE PI3Kb INHIBITOR AND THE MAPK VIA INHIBITOR, INCLUDING MEK AND RAF INHIBITORS | |
| MX2022014792A (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same. | |
| CL2016001843A1 (en) | Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal. | |
| EA201991373A1 (en) | ROR GAMMA MODULATORS (RORγ) | |
| PE20181450A1 (en) | 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| AR104172A1 (en) | COMBINATION THERAPY WITH FGFR / PD-1 FOR CANCER TREATMENT | |
| EA202091653A1 (en) | MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES | |
| AR099416A1 (en) | COMBINED THERAPY FOR RESISTANT HYPERTENSION | |
| EA201790220A1 (en) | TREATMENT OF SYMPTOMS ASSOCIATED WITH ANDROGEN-DEPRIVATION THERAPY |